Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MW151 in Healthy Volunteers
NCT04120233Phase 1Completed
- Start
- Oct 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MW151 in Alzheimer's disease (AD) and radiation-induced cognitive impairment (RICI) (6 arms). Primary endpoint: Percentage of Participants Experiencing Drug-related Serious Adverse Events at 7 days. Started Oct 2019; status: completed.
02
Drugs
MW151
03
Conditions
Alzheimer's disease (AD)radiation-induced cognitive impairment (RICI)
Beyond the preview
Go deeper on NCT04120233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04120233.